West of Scotland Cancer Centre Gartnavel General Hospital
Welcome,         Profile    Billing    Logout  
 1 Trial 
4 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Reed, Nicholas S
NCT04524442 / 2019-004073-76: Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients

Completed
4
42
Europe
arginine/lysine, LysaKare
Advanced Accelerator Applications
Gastroenteropancreatic Neuroendocrine Tumors
11/23
11/23
LIBRETTO-531, NCT04211337 / 2019-001978-28: A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer

Active, not recruiting
3
291
Europe, Canada, Japan, US, RoW
Selpercatinib, LY3527723, LOXO-292, Cabozantinib, Vandetanib
Loxo Oncology, Inc., Eli Lilly and Company
Medullary Thyroid Cancer
05/23
02/26
NCT01979393 / 2013-000762-11: IRCI Gynae Sarcomas, High Grade Uterine Sarcoma

Active, not recruiting
2
58
Europe
Cabozantinib, Placebo
European Organisation for Research and Treatment of Cancer - EORTC, Gynecologic Oncology Group, NHS Greater Glasgow and Clyde
Uterine Sarcoma
03/22
05/24
SHIELD, NCT06176625: Sight and Hearing Investigation Into Effects on Delirium

Completed
N/A
1543
US
Communication Signage, Amplifier Use
Johns Hopkins University, National Institute on Aging (NIA)
Hearing Loss, Hearing Loss, Age-Related, Hearing Disability, Delirium, Delirium in Old Age, Delirium of Mixed Origin, Delirium With Dementia, Delirium on Emergence, Delirium, Cause Unknown, Delirium Superimposed on Dementia, Delirium Confusional State, Delirium;Non Alcoholic, Hearing Loss, Bilateral, Hearing Loss, Sensorineural, Hearing Loss, Functional, Hearing Loss, High-Frequency, Hearing
12/23
12/23

Download Options